Our company attended the 19th Critical Kidney Disease and Blood Purification Conference of the Chinese Society of Nephrology.
Opening ceremony site
Recently, the 19th Critical Kidney Disease and Blood Purification Conference (CCBPC2025) of the Chinese Medical Association's Nephrology Branch was grandly held in Tianjin, and our company actively participated in this industry event. As a highly authoritative and influential professional conference in the field of nephrology, this conference brought together top experts from home and abroad, as well as key enterprises across the industry chain. Focusing on the theme of 'Improving the treatment of critically ill kidney diseases and kidney replacement therapy,' it delved into cutting-edge industry trends, directions for technological innovation, and new breakthroughs in clinical practice. It holds great significance for promoting high-quality development in the industry and serves as a key platform for grasping the pulse of developments in the field.
From left to right: Professor Sydney Tang, Professor Christopher T. Chan, Professor Rajnish Mehrotra
Based on the information conveyed at the meeting, with the increasing demand for kidney disease prevention and treatment, continuous advancements in related technologies, and the in-depth implementation of the "Healthy China" strategy, the market in the field of critical kidney disease and blood purification shows extremely broad prospects. The promotion of grassroots medical equipment deployment and standardized technical training will further stimulate market demand, bringing significant growth opportunities for industry enterprises.
Our future plans
Our company has a comprehensive range of related products, covering multiple categories including blood purification devices and consumables. These products can meet the diverse needs of different medical institutions and various clinical scenarios. Whether for basic hemodialysis treatment, cutting-edge areas such as continuous renal replacement therapy (CRRT), or routine diagnosis and treatment in primary healthcare, there are suitable products available. The complete product lineup has not only attracted widespread attention from attending experts and peers but also demonstrates our company's commitment and strength in this field.
Our future plans
This conference has given us a clearer insight into market trends and development opportunities. In the future, our company will seize the benefits of industry growth, continuously optimize our product portfolio, and contribute to the advancement of critical kidney disease and blood purification fields.
